<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355169</url>
  </required_header>
  <id_info>
    <org_study_id>1902G1721</org_study_id>
    <nct_id>NCT04355169</nct_id>
  </id_info>
  <brief_title>Naldemedine for Patients Undergoing Surgeries That Include a Bowel Resection or Bowel Transection</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Naldemedine in Patients Undergoing Surgeries That Include a Bowel Resection or Bowel Transection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy of naldemedine 1.25 mg, 2.5 mg, and 5
      mg and placebo on the time to gastrointestinal (GI) recovery following surgeries that include
      bowel resection and bowel transection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">January 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from the end of surgery to time to first toleration of solid food and first bowel movement (GI2)</measure>
    <time_frame>Up to 10 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from the end of surgery to time when the discharge order is written</measure>
    <time_frame>Up to 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants requiring postoperative reinsertion of the nasogastric tube</measure>
    <time_frame>Up to 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with nausea on Days 1 through 3</measure>
    <time_frame>Days 1 to 3 after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with vomiting on Days 1 through 3</measure>
    <time_frame>Days 1 to 3 after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants discharged by Day 10 who are readmitted for any reason within 30 days after discharge from the hospital</measure>
    <time_frame>From the discharge date (Days 1-10) up to 30 days after discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Postoperative Gastrointestinal Dysfunction</condition>
  <arm_group>
    <arm_group_label>Naldemedine 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.25 mg naldemedine twice daily (BID) beginning on the day of surgery and for up to a maximum of 10 days post-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naldemedine 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naldemedine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naldemedine</intervention_name>
    <description>Orally disintegrating tablets administered orally twice a day.</description>
    <arm_group_label>Naldemedine 1.25 mg</arm_group_label>
    <arm_group_label>Naldemedine 2.5 mg</arm_group_label>
    <arm_group_label>Naldemedine 5 mg</arm_group_label>
    <other_name>S-297995</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally disintegrating tablets administered orally twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery
             under general anesthesia:

               -  partial small or large bowel resection with primary anastomosis

               -  radical cystectomy requiring bowel transection with primary anastomosis

          -  Planned to be managed postoperatively with an enhanced recovery protocol, which, at a
             minimum, includes all of the following elements:

               -  early removal of the nasogastric tube, which is defined as removal of the
                  nasogastric tube at the end of surgery

               -  early ambulation, which is defined as ambulation on Day 1

               -  early diet advancement on Day 1

          -  Planned to receive primary postoperative pain management with opioid analgesia
             administered by any route.

          -  American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a
             normal healthy patient, a patient with mild systemic disease, and a patient with
             systemic disease, respectively).

        Exclusion Criteria:

          -  Scheduled for endoscopic or laparoscopic surgery.

          -  Emergency surgery.

          -  Complete bowel obstruction

          -  Previous major abdominal surgery (eg, gastrectomy, gastric bypass, gastric sleeve, lap
             banding, Whipple, pancreatic resection, total/subtotal colectomy, hemicolectomy,
             extensive bowel resection).

          -  More than 3 doses of an opioid (regardless of the route of administration) during the
             7 days prior to surgery.

          -  Pregnancy or lactation.

          -  Presence of peritoneal catheter (eg, for dialysis or chemotherapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <phone>800-849-9707</phone>
    <email>Shionogiclintrials-admin@shionogi.co.jp</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bowel resection</keyword>
  <keyword>Gastrointestinal recovery</keyword>
  <keyword>peripherally acting mu-opioid receptor antagonist</keyword>
  <keyword>Bowel transection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

